ENTRADA THERAPEUTICS, INC. Expense Breakdown
No Expense Breakdown for TRDA on this site yet.
- 2026-06-30: Reportable $10.49M.
- 2025-06-30: Reportable $10.92M.
Source checked: the stored Expense Breakdown page for TRDA.
Expenses by product
General and Administrative Expense: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $10.49M |
| 2025-06-30 | $10.92M |
Income Tax Expense (Benefit): each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $35.00K |
| 2025-06-30 | $178.00K |
Research and development: each quarter (3 month)
| Quarter end | Reportable |
|---|---|
| 2026-06-30 | $35.37M |
| 2025-06-30 | $37.88M |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Cue Biopharma, Inc. (CUE) | United States | $0.243B | -1.01 |
| MACROGENICS INC (MGNX) | United States | $0.242B | -20.11 |
| Pyxis Oncology, Inc. (PYXS) | United States | $0.244B | |
| Camp4 Therapeutics Corp (CAMP) | United States | $0.240B | -2.12 |
| Lyell Immunopharma, Inc. (LYEL) | United States | $0.248B | -1.32 |
| Sionna Therapeutics, Inc. (SION) | United States | $0.236B | -20.37 |
| SIGA TECHNOLOGIES INC (SIGA) | United States | $0.234B | -93.33 |
| Cartesian Therapeutics, Inc. (RNAC) | United States | $0.231B | -2.04 |
| Akebia Therapeutics, Inc. (AKBA) | United States | $0.255B | -10.35 |
| Keros Therapeutics, Inc. (KROS) | United States | $0.229B | -2.55 |